PROCEPT BioRobotics reports strong financial performance with a 55% revenue increase for Q1 2025.

From GlobeNewswire: 2025-04-24 07:00:00

PROCEPT BioRobotics reported total revenue of $69.2 million for the first quarter of 2025, a 55% increase from the prior year. The U.S. saw a 61% increase in handpiece revenue and sold 43 new robotic systems. International revenue also increased by 104%. The company raised its 2025 revenue guidance to $323 million.

The company’s CEO, Reza Zadno, cited strong performance in the first quarter and increased procedural momentum. The U.S. launch of the Hydros™ system is gaining traction, with corporate IDN multi-unit orders accounting for 45% of placements. This signals a growing strategic focus on Aquablation® therapy among leading health systems.

First quarter 2025 financial results showed a 55% revenue increase compared to the prior year, totaling $69.2 million. U.S. revenue amounted to $60.3 million, with handpiece and consumable revenue up by 61%. Gross margin for the quarter was 64%, driven by operational efficiencies and higher selling prices on U.S. robotic systems.

Operating expenses in the first quarter of 2025 were $71.6 million, up from $52.7 million in the prior year period. Net loss for the quarter was $24.7 million, with an adjusted EBITDA loss of $15.8 million. Cash, cash equivalents, and restricted cash balances as of March 31, 2025, totaled $319.2 million, with long-term borrowings at $52.0 million.

For the full year 2025, PROCEPT BioRobotics projects revenue of $323.0 million, a 44% increase from the prior year. Gross margin is expected to be around 64.5%, with operating expenses of approximately $300.0 million. Adjusted EBITDA loss for the full year is estimated to be ($35.0) million. The company will host a conference call on April 24, 2025, to discuss these financial results.



Read more at GlobeNewswire:: PROCEPT BioRobotics Reports First Quarter 2025 Financial